The European "clinical trial" regulation; relationship with the Jardé Act: a Giens workshop
Therapie. 2015 Jan-Feb;70(1):21-36.
doi: 10.2515/therapie/2014234.
Epub 2015 Feb 16.
[Article in
English,
French]
Authors
François Lemaire
1
, Brigitte Marchenay
2
, Olivier Chassany
3
; participants of round table N°2 of Giens XXX:; Philippe Barthélémy
4
, Mohamed Bouzzagou
5
, Denis Comet
6
, Cécile Delval
7
, Claude Dubray
8
, Cécile Fouret
9
, Elisabeth Frija-Orvoen
10
, Laetitia Gambotti
11
, Véronique Lamarque
12
, Geneviève d'Orsay
13
, Valérie Plattner
14
, Claire Sibenaler
15
, Jacques Roux
16
, Frédérique Thoby
17
Affiliations
- 1 Université Paris Est, Créteil, France.
- 2 Laboratoire Roche, Boulogne Billancourt, France.
- 3 Université Paris Diderot, Paris, France - Assistance Publique - Hôpitaux de Paris, Paris, France.
- 4 Laboratoire AstraZeneca, Rueil Malmaison, France.
- 5 Laboratoire Boehringer-Ingelheim, Reims, France.
- 6 AFCROs, Axonal, Nanterre, France.
- 7 ANSM, Saint Denis la Plaine, France.
- 8 Centre d'Investigation Clinique, Clermont-Ferrand, France.
- 9 Medtronic, Boulogne Billancourt, France.
- 10 CNCPP, Paris, France.
- 11 Assistance Publique - Hôpitaux de Paris, Paris, France.
- 12 Eval Santé, Croissy-sur-Seine, France.
- 13 Voluntis, Suresnes, France.
- 14 Hospices Civils, Lyon, France.
- 15 LEEM, Les Entreprises du Médicament, Paris, France.
- 16 Laboratoire Glaxosmithkline, Marly-le-Roi, France.
- 17 Laboratoire Novartis, Rueil Malmaison, France.
Abstract
In May 2014, the European Union Parliament and Council published a new regulation on clinical trials on medicinal products for human use, which is designed to replace Directive 2001/20/EC. It will not come into effect until 2016. Nevertheless, it is essential to examine its relationship with national legislation, i.e. the Jardé Act, whose implementation has been delayed pending publication of the European regulation. The Giens workshop identified and examined the various issues that this relationship is bound to raise. In particular, it looked at trial methodology assessment procedures, the working relationship between the French National Agency of Drug Safety and Health Products (Agence Nationale de Sécurité du Médicament et des Produits de Santé, ANSM) and ethics committees during the authorization application evaluation phase, review of post-authorization/registration studies on medicinal products and medical devices, and data transparency.
© 2015 Société Française de Pharmacologie et de Thérapeutique.
MeSH terms
-
Access to Information / legislation & jurisprudence
-
Clinical Trials as Topic / legislation & jurisprudence*
-
Clinical Trials as Topic / standards
-
Computer Security / legislation & jurisprudence
-
Ethics Committees, Clinical / legislation & jurisprudence
-
Ethics Committees, Clinical / organization & administration
-
Ethics Committees, Clinical / standards
-
Ethics Committees, Research / legislation & jurisprudence
-
Ethics Committees, Research / organization & administration
-
Ethics Committees, Research / standards
-
European Union
-
France
-
Government Agencies
-
Human Experimentation / legislation & jurisprudence
-
Humans
-
Language
-
Medical Device Legislation
-
Observational Studies as Topic / legislation & jurisprudence
-
Research Design / standards